FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Suggestions for Patient-Focused Drug Guidances

Stakeholders comment on and make suggestions to improve an FDA discussion document on patient-focused drug development.

Human Drugs

2 New CDER Bioresearch Monitoring Documents

FDA issues a guidance and technical conformance guide on bioresearch monitoring electronic submissions.

Human Drugs

Court Rejects Amgen Sensipar Exclusivity

The DC federal court grants FDA summary judgment supporting its decision not to grant pediatric exclusivity to Amgens Sensipar.

Marketing

FDA Calls Xtampza ER Booth False, Misleading

The CDER Office of Prescription Drug Promotion cautions Collegium Pharmaceuticals about a misleading exhibit booth for Xtampza ER.

Human Drugs

DoJ Asked to Reopen Forest Celexa Case

A plaintiffs law firm says Forest Pharmaceuticals misled the Justice Department and FDA when it negotiated 2010 settlements involving misbranding of i...

Medical Devices

Pacific Hospital Supply QS Issues

FDA warns Taiwans Pacific Hospital Supply about Quality System violations in its manufacturing of disposable medical supplies.

Human Drugs

CGMP Violations in Casmara Cosmetics Inspection

FDA warns Spains Casmara Cosmetics about CGMP and other violations in its production of finished pharmaceuticals.

Federal Register

Regulatory Review Period Determined for Darzalex

Federal Register notice: FDA determines for patent extension purposes that the regulatory review period for Genmabs Darzalex (daratumumab) is 1,939 da...

Federal Register

Regulatory Review Period Determined for Portrazza

Federal Register notice: FDA determines for patent extension purposes that the regulatory review period for Eli Lillys Portrazza (necitumumab) is 2,53...

Federal Register

Laboratory Reorganization Under FDA Program Alignment

Federal Register notice: FDA announces that its Office of Global Regulatory Operations and Policy, Office of Regulatory Affairs, and Office of Regulat...